Our results suggest that inhibiting LRRK2 kinase activity through enhanced Rit2 expression is beneficial against ALP defects, aSyn pathology and could target not only G2019S-LRRK2 PD, but also idiopathic PD. Here, LRRK2 is linked to Parkinson disease.